- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04746352
Effectiveness of Self-myofascial Release Combined With Biofeedback and Electrical Stimulation for the Management of MFPP
February 5, 2021 updated by: Yang Shen, Zhongda Hospital
Effectiveness of Self-myofascial Release Combined With Biofeedback and Electrical Stimulation for the Management of Myofascial Pelvic Pain
Myofascial pelvic pain (MFPP) caused by myofascial trigger points (MTrPs) is a major contributor of female chronic pelvic pain.
However, the effect of the patient's self-myofascial release (SMFR) is not clear.
Current study is to investigate the effect of SMFR combined with biofeedback and electrical stimulation (BES) therapy compared with BES alone in patients with MFPP.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
68 patients was enrolled and randomly allocated into two groups: BES-SMFR group (n=34) and BES group (n=34).
Every patient received 4 weeks treatment, and was evaluated at baseline (T0), 4-week post-intervention (T4) and 12-week follow-up (T12).
The primary outcome was pain intensity.
The secondary outcomes were degree in activation of MTrPs, surface electromyography (sEMG) levels, and Patient Global Impression of Improvement (PGI-I).
Study Type
Interventional
Enrollment (Actual)
82
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Zhongda Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- age between 18 and 70 years;
- presence of persistent chronic pelvic pain ≥ 4 points on a 10 points numeric rating scale for at least 3 months;
- at least one active MTrP in one of muscle group including obturator internus, levator ani, piriformis, coccygeus on pelvic examination.
Exclusion Criteria:
- diseases of the urinary, genital, colorectal systems;
- prolapse of the pelvic organ;
- a history of pelvic rehabilitation within the 3 months prior to study;
- psychiatric disorders;
- pregnancy;
- breastfeeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: BES-SMFR group
Using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs.
Three standardized programs were used in our study: (1) Tens electricity (first program): 5 min of 50-280 Hz frequency and a pulse duration of 50 µs.
(b) Endorphin electricity (second program): 5 min of 1-10 Hz frequency and a pulse duration of 200 µs.
(c) Spasmolysis electricity (third program): 5 min of 1-2 Hz frequency and a pulse duration of 300 µs.
At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
|
For the BES intervention, it was performed using the same Vishee neuro-muscle stimulator as the sEMG assessment with a vaginal probe was inserted into the vagina and placed close to the PFMs.
At the same time, patients could learn about their neuromuscular activity through the biofeedback instrument, abdominal breathing for 5 sec was necessary when PFMs were overactive.
BES was performed once every 2 days for 4 weeks.
|
|
Active Comparator: BES group
|
First, a standardized and structured vaginal examination was performed by digital palpation to identify pelvic floor active MTrPs, and then pain mapping was developed for the patient's use.
Second, patients were required to participate in intensive training regarding myofascial release techniques.
Following the training, SMFR was regularly performed by at home for 5 minutes daily for 4 weeks.
SMFR was confirmed with patients at all their follow up visits.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The change of pain intensity
Time Frame: Up to 12 weeks
|
Pain intensity was calculated by using the visual numeric rating scale (NRS), which is a 11-point rating scale ranging from "0" (no pain) to "10" (worst pain imaginable) .
For each patient, the NRS referred to pain elicited while palpating bilaterally each PFM groups and was averaged pain across all the muscles.
Upon palpation, the patient was asked to place in a resting, semi-recumbent position with legs supported by pillow to prevent excessive tension in the PFMs.
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The degree in activation of MTrPs
Time Frame: Up to 12 weeks
|
MTrPs were considered as active when the following criteria was met: (1) Presence of a palpable taut band in the muscle; (2) Presence of a hypersensitive spot in the taut band; (3) Local twitch response elicited by snapping palpation; (4) Reproduction of the typical referred pain pattern in response to the compression of tender spots; and (5) Spontaneous presence of the typical referred pain pattern.
Active MTrPs localized mainly in the bilateral obturator internus, levator ani, piriformis and coccygeus were assessed respectively by pelvic floor manual palpation.
Using the inclusion criterion of having active MTrPs at least one in the bilateral muscles as a cutoff point.
|
Up to 12 weeks
|
|
Surface electromyography (sEMG) levels of the PFMs
Time Frame: Up to 12 weeks
|
The PFMs sEMG assessment was performed based on Glazer protocol by using the device of Vishee neuro-muscle stimulator (MyoTrac Infiniti, model SA9800, Thought Technology Ltd., Montreal, Canada).
The sEMG amplitude mean value based on Glazer protocols for selected tasks were follows: 60-s pretest resting baseline, assessing the resting amplitude of PFM before the test sequence; 5 rapid contractions (quick flicks), assessing fast muscles function; 60-s endurance contraction, assessing slow muscles function; 60-s posttest resting baseline, assessing the resting amplitude of PFM after the test sequence.
|
Up to 12 weeks
|
|
The score of Patient Global Impression of Improvement (PGI-I)
Time Frame: Up to 12 weeks
|
PGI-I is a patient self-reporting evaluation that assesses overall perception of response to treatment according to a 7-point scale, including very much worse, much worse, a little worse, no change, a little better, much better or very much better, with lower scores indicating more favorable outcomes.
Better response to treatment was considered when a PGI-I score < 3 (very much better or much better).
|
Up to 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Yang Shen, MD,PhD, Zhongda Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2017
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2019
Study Registration Dates
First Submitted
February 1, 2021
First Submitted That Met QC Criteria
February 5, 2021
First Posted (Actual)
February 9, 2021
Study Record Updates
Last Update Posted (Actual)
February 9, 2021
Last Update Submitted That Met QC Criteria
February 5, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Zhongda Hospital
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myofascial Pelvic Pain
-
Delta University for Science and TechnologyCompletedPelvic Floor Myofascial PainEgypt
-
University of California, Los AngelesNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
Washington University School of MedicineCompletedMyofascial Pain | Pelvic Pain | Pelvic Floor Myofascial PainUnited States
-
University of California, Los AngelesRecruiting
-
Boston Urogynecology AssociatesAllerganUnknownMyofascial Pelvic PainUnited States
-
Riphah International UniversityRecruitingMyofascial Trigger Point Pain | Chronic Pelvic PainPakistan
-
Munzur UniversityIstanbul University - Cerrahpasa (IUC)CompletedMyofascial Trigger Point Pain | Chronic Pelvic Pain SyndromeTurkey
-
Akdeniz UniversityPamukkale UniversityCompletedInvestigation of Acute Effects of Myofascial Trigger Point Release in Women With Chronic Pelvic PainPelvic Pain | Myofascial Trigger Point Pain | Pelvic Floor; RelaxationTurkey
-
University Hospitals Cleveland Medical CenterAllerganCompletedMyofascial Pain Syndromes | Trigger Point Pain, Myofascial | Myofascial Trigger Point PainUnited States
-
University of Sao PauloTerminated
Clinical Trials on BES-SMFR
-
Virginia Commonwealth UniversityNational Institute on Disability, Independent Living, and Rehabilitation... and other collaboratorsRecruitingTetraplegia/TetraparesisUnited States
-
Centre Hospitalier Universitaire de NīmesCompleted
-
Sumitomo Pharma America, Inc.BehaVR LLCCompletedSocial Anxiety Disorder (SAD)United States
-
Yeditepe UniversityNot yet recruiting
-
The Cleveland ClinicRecruitingFacial ParalysisUnited States
-
Debiopharm International SACompleted
-
Checkpoint Surgical Inc.Congressionally Directed Medical Research ProgramsRecruitingNerve Injury | Peripheral Nerve Injuries | Nerve Palsy | Peripheral Nerve Injury Upper LimbUnited States
-
Checkpoint Surgical Inc.Congressionally Directed Medical Research ProgramsActive, not recruitingNerve Injury | Ulnar Neuropathies | Cubital Tunnel Syndrome | Nerve CompressionUnited States
-
Yonsei UniversityCompletedIschemic Heart DiseaseKorea, Republic of
-
Xiongjing JiangYinyi(Liaoning) Biotech Co., Ltd.CompletedIschemic Stroke | Vertebral Artery Stenosis